Gainesville, FL/May 11,2021 – Evren today announced that it was selected to participate in the 2021 Rosenman Innovators cohort, a group of early-stage companies chosen for their innovative technologies and patient impact.
2021 is the sixth year for the Rosenman Innovator selection cycle. To be eligible, companies must be developing technologies in the medical device, diagnostics, digital health, or health services spaces, and must be seeking funding from seed stage to Series A. The final 10-12 finalists were selected after a rigorous application and pitching process that began in January.
The Rosenman Institute was named one of the top life science accelerators in the US by CypherBio. Others in the top 10 include JLABS, Y Combinator, and Medtech Innovator. Evren was also recently selected as a finalist to pitch at the MedTech Innovator Road Tour (out of over 1,200 applications) and await the decision on whether they have made it to the MedTech Innovator Showcase.
Blythe Karow, President & CEO, will be presenting Evren’s recent progress and investment summary at the Rosenman Symposium on June 10th. “It is a great honor to be selected as a Rosenman Innovator and I’m excited for the opportunity to work with the excellent partners and coaches connected to the Rosenman Institute for our accelerator program and final pitch.” The Rosenman Innovators receive customized and strategic coaching in communications, product development, IP, clinical/regulatory, reimbursement, marketing, and business strategy from our network of experts.
"We are thrilled to be able to help such a dynamic group," said Christine Winoto, founder and director of the UCSF Rosenman Institute. "We are excited to connect this year's Rosenman Innovators with our network of investors, who often invest, and sometimes even lead the Series A rounds. We have seen many companies in our past cohorts make great progress and reach their milestones, such as obtaining FDA approval. Several have products and services currently in the market."
About the Rosenman Institute
The UCSF Rosenman Institute, a QB3 health technology initiative at the University of California, San Francisco, is a community of investors, clinicians, and technology entrepreneurs who create solutions for unmet clinical needs. Its mission is to drive innovation and education and improve patient care by helping entrepreneurs from concept to commercialization. No UC affiliation is required to obtain support from the UCSF Rosenman Institute.
About Evren Technologies
Evren Technologies, a development stage company, is advancing the treatment of PTSD by delivering cutting-edge VNS technology through a user-friendly and intelligent hardware and software platform that is easy to use and personalized. Our initial medical device - the Phoenix® - delivers transcutaneous auricular vagal nerve stimulation (taVNS) in a discreet earbud design. Pairing the Phoenix with our PTSD symptom tracking app will allow for reimbursable remote clinician monitoring and the establishment of a leading PTSD database that collects biosignals, symptom tracking, triggering events, and therapy effectiveness.
M. Blythe Karow
President and CEO
Evren Technologies, Inc.